Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Tax Provisions: 2014-2025

Historic Tax Provisions for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Tax Provisions fell 345.80% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 191.94%. This contributed to the annual value of $19.4 million for FY2024, which is 227.09% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Tax Provisions is -$6.5 million, which was down 135.40% from $18.4 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Tax Provisions high stood at $18.4 million for Q2 2025, and its period low was -$6.5 million during Q3 2025.
  • In the last 3 years, Theravance Biopharma's Tax Provisions had a median value of $1.4 million in 2023 and averaged $3.3 million.
  • In the last 5 years, Theravance Biopharma's Tax Provisions slumped by 7,142.86% in 2022 and then skyrocketed by 29,260.00% in 2023.
  • Theravance Biopharma's Tax Provisions (Quarterly) stood at -$200,000 in 2021, then skyrocketed by 89.50% to -$21,000 in 2022, then skyrocketed by 16,738.10% to $3.5 million in 2023, then spiked by 305.29% to $14.2 million in 2024, then crashed by 345.80% to -$6.5 million in 2025.
  • Its Tax Provisions stands at -$6.5 million for Q3 2025, versus $18.4 million for Q2 2025 and -$600,000 for Q1 2025.